DOI.org (Crossref) , International Archives of Allergy and Applied Immunology , vol
1,2 Both are licensed in the UK for type 2 diabetes only
The difference between the two drugs manufactured by Novo Nordisk is their dosages and intended uses
Upon release, arachidonic acid serves as a substrate for several enzymatic pathways that produce bioactive lipid mediators known as eicosanoids
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications that are effective treatment for patients with type 2 diabetes mellitus (T2DM) and weight control by stimulating insulin secretion, suppressing glucagon secretion, delaying gastric emptying and decreasing appetite. To investigate whether GLP-1RAs might have a positive impact in patients with knee OA, Zhu and colleagues analyzed data from a prospective, observational, multicenter study called the Shanghai Osteoarthritis Cohort
Hypertension management in Africa must move beyond pillsit must integrate metabolic awareness, community culture, and coordinated prevention